ABSTRACT

New radiation technologies have been developed and adopted for clinical use in prostate cancer treatment in response to a need to deliver dose escalated radiation therapy while minimizing treatment related morbidity. The goal of this article is to examine the currently available evidence comparing dosimetric and patient outcomes of newer versus older radiation technologies in prostate cancer. Overall, although a body of dosimetry studies have demonstrated the ability of newer versus older technologies to reduce radiation doses delivered to the rectum and bladder, more studies are needed to demonstrate that these dosimetric benefits translate into improved patient outcomes.